Targeted therapy has changed the treatment approach for chronic lymphocytic leukemia (CLL), showing higher efficacy and safety compared to standard chemoimmunotherapy. Until recently, an important question remained unanswered: whether the administration of Bruton tyrosine kinase inhibitors (BTKi) after previous therapy with the BCL-2 inhibitor venetoclax provides sufficient clinical effect.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
